Close Menu

NEW YORK (GenomeWeb) – Veracyte reported after the close of the market on Monday that its second quarter revenues rose 25 percent year over year, driven in part by strong sales growth of its Afirma genomic classifier.

For the three months ended June 30, the company reported revenues of $18.4 million, up from $14.7 million in Q2 last year and beating the consensus Wall Street estimate of $18.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.